Alector Inc.
ALECNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for ALEC. That does not mean none is planned.
Get an email about ALEC's next catalysts
Track Alector (ALEC) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 2 past
ALEC Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.23 | FQ end Sep/2026 | Call: tbd
How ALEC's past catalysts played out
Market Overview
Stock performance and key metrics
AL001
Frontotemporal Dementia
AL002
Alzheimer Disease
GSK4527226
Alzheimer's Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
AL001 | Phase 3 | Frontotemporal Dementia | - | - |
AL002 | Phase 2 | Alzheimer Disease | - | - |
GSK4527226 | Phase 2 | Alzheimer's Disease | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Alector Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Alector Inc.'s (ALEC) pipeline across Phase 3, Phase 2. Its lead program is AL001 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Alector Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Alector Inc. (ALEC) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ALEC biotech catalysts?→
Add ALEC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Alector Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.